Annals of Allergy, Asthma & Immunology

06/18/2026

Do compromised ciliated cells and aberrant proliferation of basal cells drive eosinophilic inflammation in response to Type 2 inflammation in patients with allergic rhinitis combined with asthma? Learn more:

06/16/2026

In a cohort of 1,200 children on OIT at a tertiary pediatric hospital with robust OIT and EoE programs, the rate of newly diagnosed EoE during OIT was found to be 0.7%, which is lower than prior studies. Learn more:

In the past decade, significant progress has occurred with using oral immunotherapy (OIT) in the treatment of IgE–mediated food allergies. Eosinophilic esophagitis (EoE) is a known potential adverse effect of OIT.

06/11/2026

This study was a prospective, longitudinal cohort embedded within the Hong Kong Drug Allergy Delabelling Initiative. Adults referred for suspected penicillin allergy underwent standardized evaluation including skin test and drug provocation test. Learn more.

Inaccurate penicillin allergy (PA) labels are associated with clinical and public health burdens. Although delabeling programs are effective, long-term data on the sustainability of delabeling and patient-centered outcomes remain limited.

06/09/2026

There have been significant breakthroughs in understanding the pathophysiology of hereditary angioedema in the past several years. This Yardstick provides evidence-based, expert opinion on how to diagnose and manage pediatric and adolescent hereditary angioedema.

There have been significant breakthroughs in understanding the pathophysiology of hereditary angioedema in the past several years. Owing to this, patients now have several therapeutic options for management of both acute attacks and prophylactic therapy. Navigating these options can be confusing to....

06/04/2026

Venom immunotherapy remains the only disease-modifying treatment for Hymenoptera (stinging insect) venom allergy. This study evaluates safety and efficacy of a novel 4-day outpatient VIT buildup protocol compared with established inpatient rush and ultrarush regimens.

Hymenoptera stings can cause severe systemic reactions, including life-threatening anaphylaxis. Venom immunotherapy (VIT) remains the only disease-modifying treatment for Hymenoptera venom allergy. Conventional outpatient VIT buildup protocols are safe and well-tolerated but require prolonged buildu...

06/02/2026

This review considers how biologic therapies have improved outcomes in severe asthma, and what research is needed to improve clinical remission rates. How can patient selection help target the underlying biological process in order to optimize the impact of biologic therapy?

Severe asthma management has changed dramatically over the last decade following the introduction of T2 directed biologic therapies. This has enabled more ambitious treatment goals including on-treatment clinical remission in severe asthma. Definitions of clinical remission have invariably included....

05/28/2026

Annals of Allergy, Asthma & Immunology’s commitment to aiding clinical allergists in their care of patients is well reflected in this month’s edition, which is dedicated to the treatment of asthma. Find out what's new in the care of patients with asthma.

Annals of Allergy, Asthma & Immunology’s commitment to aiding clinical allergists in their care of patients is well reflected in this month’s edition, which is dedicated to the treatment of asthma.

05/26/2026

Is there cross-reactivity between amoxycillin and piperacillin-tazobactam? If so, how can an allergist best protect those at risk? Learn how this study aims to establish a link between the two and what the results show for safer patient care.

Amoxicillin (AX) is the most frequently prescribed β-lactam antibiotic in the USA and Europe and a leading cause of drug-induced hypersensitivity. Although cross-reactivity between aminopenicillins and ureidopenicillins can be considered unlikely based on side-chain dissimilarity, clinical data rem...

05/21/2026

Longitudinal changes in percentage of forced expiratory volume in 1 second allows clustering of patients with severe asthma into 3 groups with disparate clinical and inflammatory profiles, which may drive treatment choice.

Severe asthma is a heterogeneous disease with variable clinical manifestations and treatment responses. Long-term assessment of lung function trajectories may help define phenotypic and endotypic subgroups.